Abstract Approximately 10–50% of patients treated for early-stage (I–III), resectable non-
small cell lung cancer (eNSCLC) will develop locoregional recurrence. There is a lack of …

Over the years, many in vitro and in vivo studies have shown the antineoplastic effects of
cannabinoids (CBDs), with reports advocating for investigations of combination therapy …

Lung cancer is the second most common, and the deadliest, disease globally. Because it is
often diagnosed late, surgical resection is not a viable treatment option for∼ 75% of …

The benefit of local ablative therapy (LAT) for oligo-recurrence has been investigated and
integrated into the treatment framework. In recent decades, stereotactic body radiation …

It has been reported that upregulation of wingless‑type protein 5a (Wnt5a) is associated with
poor prognosis in patients with non‑small cell lung cancer (NSCLC). Wnt5a expression is …

Purpose The optimal treatment for hilar or mediastinal lymph node (LN) recurrence
developing after stereotactic body radiotherapy (SBRT) for stage I non-small cell lung cancer …

Locoregional recurrence of non–small‐cell lung cancer (NSCLC) after complete resection
lacks standard treatment. Durvalumab after chemoradiotherapy (CRT) or CRT alone is often …

A standard treatment for patients with early‑stage non‑small cell lung cancer (NSCLC) who
undergo surgery, and subsequently develop local failure or intrathoracic oligo‑recurrence …

Background Standard therapy for stage III non-small cell lung cancer with chemotherapy
and conventional radiation has suboptimal outcomes. We hypothesized that a combination …

Background Ultracentral (UC) tumors, a subset of central lung tumors defined as those that
abut the proximal bronchial tree (PBT), have been contraindicated for stereotactic body …